Stoke Therapeutics (STOK) Equity Ratio (2018 - 2026)

Stoke Therapeutics has reported Equity Ratio for 9 years, with the latest figure at 0.89 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 3.54% year-over-year to 0.89; the trailing twelve-month figure through Mar 2026 stood at 0.89 (up 3.54% YoY), and the FY2025 full-year result was 0.84, changed 0.12% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.89, up from 0.84 in the prior quarter.
• The five-year high for Equity Ratio was 0.89 in Q1 2026, with the low at 0.68 in Q1 2024.
• Average Equity Ratio over 5 years is 0.78, with a median of 0.76 recorded in 2022.
• Year-over-year, Equity Ratio decreased 22.84% in 2022 and advanced 25.79% in 2025.
• Tracing STOK's Equity Ratio over 5 years: stood at 0.72 in 2022, then fell by 3.2% to 0.7 in 2023, then rose by 20.69% to 0.84 in 2024, then slipped by 0.12% to 0.84 in 2025, then increased by 5.76% to 0.89 in 2026.
• The last three Equity Ratio figures came in at 0.89 (Q1 2026), 0.84 (Q4 2025), and 0.86 (Q3 2025), per Business Quant data.

Peer Comparison